Mahana Therapeutics Plans To Use $61M In Series B Financing To Launch IBS Treatment App
Executive Summary
Mahana is planning a 2022 nationwide launch of its FDA-cleared prescription digital therapeutic for treating symptoms of irritable bowel syndrome.
You may also be interested in...
Gut-Brain Connect: metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia explained their plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.
Gut-Brain Connect: How metaMe’s Digital Therapeutic Hopes To Rewire IBS Treatment
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia discuss with Scrip plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.
Exec Chat: New CEO Of Digital Therapeutics Alliance Says Reimbursement Remains Big Issue
In an interview with Medtech Insight, Andy Molnar, new CEO of the Digital Therapeutics Alliance, outlines some of the big issues facing the digital therapeutics industry, which has seen tremendous growth during the pandemic.